StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) stock

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.71+0.10 (+0.26%)

Close on Nov 17, 2026Market cap $27.96BP/E –Yield –

Roivant Sciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Roivant Sciences's price to sales ratio was 444.3× on Sep 30, 2025, against 235.5× a year earlier. Over the last 4 years it ranged from 41.7× to 444.3×, with a median of 135.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Sep 30, 2025444.3×+210.1
2024Dec 31, 2024234.2×+105.1
2023Dec 29, 2023129.0×+17.4
2022Dec 30, 2022111.6×−50.3
2021Dec 31, 2021162.0×–

More Roivant Sciences figures

See a number that looks wrong?